AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A method of treating pouchitis in a human ~~in need thereof~~, comprising:

identifying a human having chronic, unremitting pouchitis wherein said human has a Pouchitis Disease Activity Index score of at least 7; and

rectally administering to said human a pharmaceutical composition ~~suitable for rectal use~~, wherein said composition comprises ~~the~~ an antisense oligonucleotide ~~of~~ having the nucleobase sequence recited in SEQ ID NO: 1, wherein the treatment reduces the occurrence of one or more clinical symptoms selected from the group consisting of stool frequency, rectal bleeding, fecal urgency, abdominal cramps, and fever, and wherein said treatment reduces said PDAI score to less than 7.

2. (Original) The method of Claim 1, wherein said composition is an enema.

3. (Original) The method of Claim 1, wherein said composition is a suppository.

4-6. (Cancelled).

7. (Original) The method of Claim 1, wherein said composition further comprises a penetration enhancer.

8. (Original) The method of Claim 7, wherein said penetration enhancer is a surfactant, fatty acid, bile salt, chelating agent or non-chelating non-surfactant.

9. (Previously Presented) The method of Claim 1, wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

10. (Previously Presented) The method of Claim 9, wherein the modified internucleoside linkage is a phosphorothioate linkage.

11. (Previously Presented) The method of Claim 1, wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

12. (Previously Presented) The method of Claim 11, wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

13. (Previously Presented) The method of Claim 1, wherein the antisense oligonucleotide is a chimeric oligonucleotide having a plurality of 2'-deoxynucleotides flanked on each side by at least one nucleotide having a modified sugar moiety.

14. (Previously Presented) The method of Claim 13, wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

15. (Previously Presented) The method of Claim 1, wherein the antisense oligonucleotide comprises at least one modified nucleobase.

16. (Previously Presented) The method of Claim 15, wherein the modified nucleobase is a 5-methylcytosine.

17. (Previously Presented) The method of Claim 1, wherein the antisense oligonucleotide is in a salt form.

18-24. (Canceled).

25. (New) The method of claim 1, wherein said treatment reduces said PDAI score by at least 6.

26. (New) The method of claim 1, wherein said treatment reduces the endoscopy component of said PDAI score.

27. (New) The method of claim 26, wherein said treatment reduces the endoscopy component of said PDAI score to zero.

28. (New) The method of claim 1, wherein said treatment reduces the occurrence of one or more endoscopy symptoms selected from the group of edema, mucus exudate, granularity, friability, loss of vascular pattern, and ulceration.

29. (New) The method of claim 28, wherein said treatment eliminates the occurrence of one or more endoscopy symptoms selected from the group consisting of edema, mucus exudate, granularity, friability, loss of vascular pattern, and ulceration.

30. (New) The method of claim 1, wherein said treatment reduces the clinical symptom component of said PDAI score.

31. (New) The method of claim 30, wherein said treatment reduces the clinical symptom component of said PDAI score to 2.

32. (New) The method of claim 1, wherein said treatment eliminates the occurrence of one or more clinical symptoms selected from the group consisting of stool frequency, rectal bleeding, fecal urgency, abdominal cramps, and fever.

33. (New) The method of claim 1, wherein said composition is an enema formulation comprising hydroxypropylmethylcellulose, and said composition is administered once daily.

34. (New) The method of claim 33, wherein said enema comprises 240 mg of said antisense oligonucleotide.

35. (New) The method of claim 1, wherein said treatment lasts for at least 3 weeks.

36. (New) The method of claim 1, wherein said treatment lasts for at least 6 weeks.

37. (New) The method of claim 1, wherein said antisense oligonucleotide is a single-stranded modified oligonucleotide.

38. (New) The method of claim 37, wherein said antisense oligonucleotide consists of 20 linked nucleosides.

39. (New) The method of claim 38, wherein each internucleoside linkage of said antisense oligonucleotide is a phosphorothioate linkage.